首页> 外文期刊>Hypertension research: Official journal of the Japanese Society of Hypertension >Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
【24h】

Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.

机译:厄贝沙坦和依非地平联合治疗可减轻Dahl盐敏感性大鼠的蛋白尿。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Angiotensin receptor blockers (ARBs) or T- and L-type calcium channel blockers (CCBs) are useful for glomerular protection; however, the protective effects of combination therapy remain unclear. In this study, Dahl salt-sensitive rats were fed a high-salt diet and were treated daily with placebo, irbesartan (60 mg kg(-1)), efonidipine (30 mg kg(-1)), irbesartan (60 mg kg(-1))+efonidipine (30 mg kg(-1)), amlodipine (3 mg kg(-1)), or irbesartan (60 mg kg(-1))+amlodipine (3 mg kg(-1)) for 4 weeks. Significant reductions in systolic blood pressure were seen in the irbesartan-, efonidipine- and amlodipine-treated groups compared with the placebo-treated group; a further significant reduction was seen in the irbesartan+efonidipine-treated group compared with the irbesartan-treated group. Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group. Furthermore, a significant attenuation of proteinuria in the irbesartan+efonidipine-treated group compared with the irbesartan-treated group was observed; this effect was not observed in the irbesartan+amlodipine-treated group. The glomerulosclerosis index was significantly attenuated by all active treatments except amlodipine. The glomerulosclerosis index in the irbesartan+efonidipine-treated group, but not in the irbesartan+amlodipine-treated group, was significantly lower than that in the irbesartan-treated group. Significant attenuations of gene expressions of p22(phox), transforming growth factor-beta, monocyte chemoattractant protein-1 and collegen I were observed in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group. Values for these parameters were reduced to control levels in the irbesartan+efonidipine-treated group. Combination therapy with ARB and T- and L-type CCB might produce a powerful renal protective effect.
机译:血管紧张素受体阻滞剂(ARB)或T型和L型钙通道阻滞剂(CCB)可用于保护肾小球。然而,联合治疗的保护作用尚不清楚。在这项研究中,达尔盐敏感性大鼠接受高盐饮食,每天用安慰剂,厄贝沙坦(60 mg kg(-1)),依非替尼(30 mg kg(-1)),厄贝沙坦(60 mg kg)进行治疗(-1))+埃非地平(30 mg kg(-1)),氨氯地平(3 mg kg(-1))或厄贝沙坦(60 mg kg(-1))+氨氯地平(3 mg kg(-1)) 4周。与安慰剂治疗组相比,厄贝沙坦,依非地平和氨氯地平治疗组的收缩压显着降低。与厄贝沙坦治疗组相比,厄贝沙坦+芬尼地平治疗组进一步降低。与安慰剂治疗组相比,厄贝沙坦和依非地平治疗组的蛋白尿明显降低,但氨氯地平治疗组则没有。此外,与厄贝沙坦治疗组相比,厄贝沙坦+芬尼地平治疗组的蛋白尿明显减少。在厄贝沙坦+氨氯地平治疗组中未观察到这种作用。除氨氯地平外,所有积极治疗均显着降低了肾小球硬化指数。厄贝沙坦+芬尼地平治疗组的肾小球硬化指数显着低于厄贝沙坦治疗组的肾小球硬化指数,而厄贝沙坦+氨氯地平治疗组则没有。在厄贝沙坦和依非地平治疗组中观察到p22(phox),转化生长因子-β,单核细胞趋化蛋白-1和collin I的基因表达显着减弱,但在氨氯地平治疗组中未观察到。这些参数的值降低至厄贝沙坦+乙苯地平治疗组的对照水平。 ARB,T型和L型CCB联合治疗可能产生强大的肾脏保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号